Form 4: Altimmune Director Mitchel Sayare Reports Stock Option Grant

Director Mitchel Sayare reports the acquisition of stock options in Altimmune, Inc.

Summary

• On September 26, 2024, Mitchel Sayare, a director of Altimmune, Inc., reported the acquisition of 34,900 stock options.
• The options have an exercise price of $6.81.
• The options vest in equal monthly installments over 12 months following the grant date, contingent upon continued service.
• Sayare also granted power of attorney to Vipin K. Garg and Andrew Shutterly to handle SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, and does not inherently convey positive or negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies to incentivize and align the interests of directors and officers with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and officers in publicly traded companies, particularly in the biotechnology industry.
• The vesting schedule of 12 months is also typical.
• Comparable companies like Madrigal Pharmaceuticals or Viking Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates